CBG or Cannabigerol is a cannabinoid very similar to CBD, also non-psychotropic, coming from the cannabis plant, which means that it cannot produce the feeling of being stoned but it can offer the benefits that this plant offers us. The levels of CBG or Cannabigerol in the hemp plant are very, very low, so it is expensive to extract, and its extract is very expensive. Read on if you are interested to know why we love this phytocannabinoid, and why we include it in products such as our CBD face cream, our CBD (and CBG) oil and our CBD balm.
Hemp or cannabis has been used to treat various pathologies, such as pain or digestive disorders, since 2900 BC. Its therapeutic effects originate from a wide variety of molecules, where not only phytocannabinoids such as CBD or CBG, but also terpenes and flavonoids from the plant play a major role. Although more than 103 different cannabinoids have been identified from hemp plants, only a few of them, such as tetrahydrocannabinol (THC), cannabidiol (CBD) and CBG, have been found to have effects on the human body.
While THC is a drug and is the only cannabinoid of the 103 identified in the cannabis plant that has psychotropic effects, CBD and CBG are legal substances that have a variety of therapeutic properties, most notably their therapeutic potential. analgesics, anti-inflammatory drugs and even in animal models its properties have been demonstrated. neuroprotective. Over the last decade, a lot of effort has been put into developing cannabis strains that produce large amounts of CBD and CBG. Ideally, these plant varieties should produce very little (less than 0.2%), if any THC at all, in order to be legal to grow in Europe.
CBG or Cannabigerol
CBG is one of many molecular compounds found in the cannabis sativa plant. It is formed by the decarboxylation of cannabigerolic acid (CBGa), the parent molecule from which other cannabinoids are synthesised. During plant growth, most of the CBG is converted into other cannabinoids, mainly into tetrahydrocannabinol (THC) or cannabidiol (CBD), leaving about 1% of CBG in the plant.
How is CBG or Cannabigerol obtained?
It is common for the focus when talking about cannabis to be on CBD and THC when growing hemp. CBG has recently started to receive more attention. The highest amount of cannabigerol is usually found in the young hemp plant. However, if more CBD and THC is to be harvested from the hemp plant, it is usually harvested at the end of the flowering phase. At this stage, much of the CBG acid (CBGa) has already been converted into the CBD and THC precursors, so the CBG content is very low, often even lower than 1%.
For this reason, research focuses on hemp varieties that develop a higher CBG content. Earlier harvesting of the plant can also lead to a higher CBG content. Often, hemp seed oil is also used as a carrier oil for CBG oils, which can also have a low CBG content. This broadens the profile of the CBG oil.
Benefits of CBG
As we have already mentioned, as with CBD, the CBG has numerous therapeutic benefits.
Among others, we find:
- It is antibacterial and antifungal
- May inhibit the growth of cancer cells
- It is anti-inflammatory
- Promotes bone growth.
- Helps to fall asleep
- It is useful in the treatment of anorexia and cachexia.
- Improves the intestinal diseases
- It is antidepressant
- Has neuroprotective potential
Thus, several research laboratories in the USA, which focus on innovative research based on CBG, claim that it is a molecule of great importance for all vertebrates because it rivals the potential with CBD and also with the terpenes (the molecules that give cannabis its aroma and also possess medicinal qualities).
Of the hundreds of unique chemicals produced by the plant species Cannabis sativa L.none plays a more fundamental role than CBG. Multiple studies have been conducted over the past three decades, especially in the major areas of analgesia (pain relief), reduction of systemic inflammation, reduction of anxiety and nausea, and cancer research. Unfortunately, none of the studies have shown such promising results that any of the above benefits can be claimed.
With each new scientific breakthrough, it has been more than demonstrated that the Cannabis plant has not only one or two molecular compounds with therapeutic properties, among which CBG or Cannabigerol is one of the most important. It is known that CBG increases the bio-dissiponibility of CBD in the blood plasma, i.e. it increases the efficacy of CBD when it is accompanied in its formula by CBG. And why does this happen? Because when CBG enters the bloodstream it undergoes some modifications in its structure, which convert it into CBD. We could say that CBG is to CBD what Vitamin D is to Calcium.
di Giacomo V, Chiavaroli A, Recinella L, Orlando G, Cataldi A, Rapino M, Di Valerio V, Ronci M, Leone S, Brunetti L, Menghini L, Zengin G, Ak G, Abdallah HH, Ferrante C. Antioxidant and Neuroprotective Effects Induced by Cannabidiol and Cannabigerol in Rat CTX-TNA2 Astrocytes and Isolated Cortexes. Int J Mol Sci. 2020 May 18;21(10):3575. doi: 10.3390/ijms21103575. PMID: 32443623; PMCID: PMC7279038.
Nachnani R, Raup-Konsavage WM, Vrana KE. The Pharmacological Case for Cannabigerol. J Pharmacol Exp Ther. 2021 Feb;376(2):204-212. doi: 10.1124/jpet.120.000340. Epub 2020 Nov 9. PMID: 33168643.
Kogan NM, Lavi Y, Topping LM, Williams RO, McCann FE, Yekhtin Z, Feldmann M, Gallily R, Mechoulam R. Novel CBG Derivatives Can Reduce Inflammation, Pain and Obesity. Molecules. 2021 Sep 15;26(18):5601. doi: 10.3390/molecules26185601. PMID: 34577072; PMCID: PMC8467477.
Perez E, Fernandez JR, Fitzgerald C, Rouzard K, Tamura M, Savile C. In Vitro and Clinical Evaluation of Cannabigerol (CBG) Produced via Yeast Biosynthesis: A Cannabinoid with a Broad Range of Anti-Inflammatory and Skin Health-Boosting Properties. Molecules. 2022 Jan 13;27(2):491. doi: 10.3390/molecules27020491. PMID: 35056807; PMCID: PMC8778347.
Jastrząb A, Jarocka-Karpowicz I, Skrzydlewska E. The Origin and Biomedical Relevance of Cannabigerol. Int J Mol Sci. 2022 Jul 19;23(14):7929. doi: 10.3390/ijms23147929. PMID: 35887277; PMCID: PMC9322760.
Russo EB, Cuttler C, Cooper ZD, Stueber A, Whiteley VL, Sexton M. Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. Cannabis Cannabinoid Res. 2022 Oct;7(5):706-716. doi: 10.1089/can.2021.0058. Epub 2021 Sep 27. PMID: 34569849; PMCID: PMC9587780.